OOIR: Observatory of International Research

Papers

(The H4-Index of AIDS is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
The need to avert emergent resistance to dolutegravir in children and adolescents with HIV	76
High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for INSTI salvage therapy	47
Elevated stress-responsive biomarkers are associated with HIV acquisition in young women in rural South Africa	46
Strategies for managing weight gain associated with antiretroviral therapy: switch or add?	44
Real world use of dolutegravir two drug regimens	43
Multisector global collaboration to advance the inclusion of pregnant and lactating people in HIV prevention research	42
Ex-vivo rectal tissue infection with HIV-1 to assess time to protection following oral preexposure prophylaxis with tenofovir disoproxil/emtricitabine	38
Reduced bone density accrual among peripubertal boys with HIV in Zimbabwe: Erratum	37
Systemic inflammation in pregnant women with HIV: relationship with HIV treatment regimen and preterm delivery	33
Trends in population HIV viral suppression: a longitudinal analysis	32
HIV-1 gp120 amplifies astrocyte elevated gene-1 activity to compromise the integrity of the outer blood–retinal barrier	32
Keeping up with Streptococcus pneumoniae in children living with HIV: Erratum	31
Comparison of dolutegravir and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV	30
Quantifying missed opportunities for tuberculosis among people with HIV in the US President's Emergency Plan for AIDS Relief	30
A new frontier in HIV care: the predictive power of renal biomarkers on heart health	30
Gut microbiota and plasma metabolites associated with bone mineral density in women with or at risk of HIV infection	29
Impact of pre-antiretroviral treatment HIV-RNA on time to successful virological suppression and subsequent virological failure – two nationwide, population-based cohort studies	29
Explaining racial and ethnic disparities in antiretroviral therapy adherence and viral suppression among U.S. men who have sex with men	28
Virtual case management: a differentiated approach to HIV prevention, treatment, and care	28
Factors influencing antiretroviral therapy switching in people with virologically suppressed HIV-1: a cross-sectional multicenter study in France	27
Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV	26
Associations between social determinants of health and comorbidity and multimorbidity in people of black ethnicities with HIV	26
Incidence and risk factors for recurrent sexually transmitted infections among MSM on HIV pre-exposure prophylaxis	25
Life expectancy of people with HIV on antiretroviral therapy in Spain	25
Long-term persistence of transcriptionally active ‘defective’ HIV-1 proviruses: implications for persistent immune activation during antiretroviral therapy	25